TheStreet Upgrades Intercept Pharmaceuticals to “Hold” (ICPT)
Several other analysts have also recently commented on the stock. Analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday. They now have a $456.00 price target on the stock, up previously from $323.00. Separately, analysts at RBC Capital raised their price target on shares of Intercept Pharmaceuticals from $425.00 to $500.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Finally, analysts at Leerink Swann upgraded shares of Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday. They now have a $445.00 price target on the stock, up previously from $270.00. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $503.00.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 10,000 shares of the stock on the open market in a transaction dated Friday, August 1st. The shares were sold at an average price of $226.72, for a total transaction of $2,267,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 4.10% on Thursday, hitting $295.01. 536,593 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock has a 50-day moving average of $233.6 and a 200-day moving average of $291.8. The company’s market cap is $5.758 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, August 11th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.44 EPS for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.